Showing results (391-400 of 523) with videos related to
Sort By:
Pageof 53
The European Respiratory Journal|August 12, 2017
EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practicePascale Tomasini, Solenn Brosseau, Julien Mazières, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 5, 2017
Multidisciplinary Tumor Board Decision Making for Postoperative Radiotherapy in Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective CohortClémence Basse, Sébastien Thureau, Suzanna Bota, et al.Cell Reports. Medicine|November 18, 2020
CD103+CD8+ TRM Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17Stéphanie Corgnac, Ines Malenica, Laura Mezquita, et al.European Journal of Cancer (Oxford, England : 1990)|March 7, 2020
Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapiesCapucine Baldini, Patricia Martin Romano, Anne-Laure Voisin, et al.The Lancet. Oncology|September 15, 2022
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trialMary O'Brien, Luis Paz-Ares, Sandrine Marreaud, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 29, 2021
Central Nervous System Metastases in Thymic Epithelial Tumors: A Brief Report of Real-World Insight From RYTHMICJose Carlos Benitez, Marie-Ève Boucher, Eric Dansin, et al.European Journal of Cancer (Oxford, England : 1990)|January 15, 2018
Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory diseaseFrançois-Xavier Danlos, Anne-Laure Voisin, Valérie Dyevre, et al.Oncotarget|April 21, 2017
Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective studyMichaël Duruisseaux, Benjamin Besse, Jacques Cadranel, et al.Journal of Experimental & Clinical Cancer Research : CR|October 26, 2023
Implementing patient derived organoids in functional precision medicine for patients with advanced colorectal cancerJérôme Cartry, Sabrina Bedja, Alice Boilève, et al.The New England Journal of Medicine|June 1, 2026
Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung CancerYi-Long Wu, Maximilian Hochmair, Yi Yang, et al.Pageof 53